Navigation Links
Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices
Date:5/20/2013

ALISO VIEJO, Calif., May 20, 2013 /PRNewswire/ -- Sequent Medical, Inc. announced today that it has received CE mark for the SL ("Single Layer") family of WEB® Aneurysm Embolization Devices, and has commenced a controlled release of these new models in select neurovascular centers in Europe.  The SL family offers a lower profile and superior navigability that will enable physicians to treat a broader range of aneurysms with the WEB platform.

The SL configurations are made possible by further advancement of Sequent Medical's proprietary MicroBraid™ technology, a dense mesh constructed from a large number of extremely fine Nitinol wires.  Unlike conventional medical braids, MicroBraid features a mix of wire diameters and high wire counts to achieve a tailored balance of compliance, porosity and profile across device sizes. 

The SL family consists of two separate product configurations, the WEB SL and WEB SLS, each with a distinct shape designed to accommodate varying aneurysm morphologies.  Both configurations are available in multiple sizes ranging from 4-11 mm and are designed for delivery through Sequent Medical's VIA microcatheters.

The WEB SL and WEB SLS will build upon the growing experience with the original dual layer WEB, now referred to as the WEB DL configuration, which has now been used to treat over 280 ruptured and unruptured aneurysms in Europe and Latin America. 

"Sequent Medical has responded to physicians' requests in developing the WEB SL configurations," said Prof Laurent Pierot , MD PhD, Head of the Department of Radiology, Maison Blanche Hospital, Reims, France.  "The SL family promises to expand the range of aneurysms physicians can treat with the WEB while continuing to offer the familiar straightforward procedure we've come to value with the WEB DL." 

"Combined with our recently introduced VIA microcatheter line, the introduction of the SL products demonstrates Sequent Medical's ongoing commitment to developing a broad portfolio of innovative catheter-based technologies for neurovascular specialists and their patients," said Tom Wilder , President and Chief Executive Officer. 

About Sequent Medical, Inc.

Founded in 2007, Sequent Medical, Inc. (www.sequentmedical.com) is a privately held venture backed medical-device company that is dedicated to the development of innovative catheter-based neurovascular technologies.  The WEB Aneurysm Embolization System and VIA Microcatheter have both received the CE mark.  They are not approved for or available for sale or use in the United States.  Sequent Medical, Inc. is headquartered in Aliso Viejo, California, and has European operations based in Bonn, Germany.

About The WEB Aneurysm Embolization System

Building upon the foundation of endovascular embolic coils, the WEB is a low porosity intrasaccular neurovascular embolization device that is designed to bridge the neck of a ruptured or unruptured intracranial aneurysm and to promote rapid, peri-procedural stasis. The WEB enables physicians to treat a broad range of intracranial aneurysms with the familiarity of an intrasaccular approach while using established biomaterials.  The WEB product portfolio consists of the original WEB DL configuration and the recently introduced WEB SL and WEB SLS offerings.    


'/>"/>
SOURCE Sequent Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt
2. Researchers Funded By The Pancreatic Cancer Action Network Leverage $9.15 Million Investment By The Organization Into $91 Million In Subsequent Pancreatic Cancer Research Funding
3. Sequent Medical, Inc. führt VIA-Mikrokatheter ein
4. Sequent Medical, Inc. lance le microcathéter VIA
5. Sequent Medical, Inc. lanza el microcatéter VIA
6. Sequent Medical, Inc. Launches VIA Microcatheter
7. Sequent Medical, Inc. Awarded U.S. Patent for MicroBraid Technology
8. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
9. Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR
10. Parametrics Medical, LLC Announces the Release of Their Coll-e-Strong Line of Soft Tissue Allografts
11. Haemonetics Completes Hemerus Medical, LLC Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... ... 2017 , ... Ridgecrest Herbals makes it a point to lead the Utah ... and support renewable energy. They believe this is a crucial part of their mission ... health issues, and maintain that destroying the environment in the pursuit of profit is ...
Breaking Medicine News(10 mins):